Nerivio is the first migraine treatment device available to members of Costco’s prescription program
NETANYA, Israel and MONTCLAIR, NJ, June 1, 2022 /PRNewswire/ — Theranicaa digital prescription therapy company developing advanced electroceuticals for migraine and other pain conditions, today announced that the Costco Member Prescription Program (CMPP) now offers Theranica’s flagship FDA-cleared product Nerivio® at an exclusive rate for Costco members, marking the first time a migraine treatment device has been offered to CMPP members.
Nerivio is a drug-free, prescription, smartphone-controlled, FDA-cleared wearable device for the treatment of episodic and chronic migraine in people ages 12 and older. Worn on the upper arm at the onset of a migraine attack, Nerivio relieves migraine and associated symptoms by using remote electrical neuromodulation to trigger an endogenous analgesic mechanism, known as conditioned pain modulation. Clinical studies have shown that Nerivio is as effective as standard-of-care pharmacological options and can be used as a stand-alone treatment or in combination with existing treatments.
“This collaboration with Costco is a major step in helping us bring effective, drug-free migraine relief to millions of teens and adults in need,” said Alon Ironi, CEO of Theranica. “Through its exceptional direct-to-customer policy, Costco provides millions of underinsured and uninsured people with affordable access to top-quality prescription therapies, offering Nerivio as their first-line therapy. Additionally, the site CMPP’s Web helps members quickly receive a prescription for Nerivio online, via a telemedicine consultation with a trained provider.”
The CMPP is a drug discount program that offers Costco members and their dependents the opportunity to obtain lower prices on prescription drugs at participating pharmacies. All Costco members now have access to Nerivio at an exclusive price, following a prescription from their healthcare provider or through a telemedicine consultation, and fulfilled by Miller’s Pharmacy online. Controlled by a smartphone app, Nerivio allows patients to treat their migraine attacks and monitor their results with an integrated migraine diary that is easily shared with healthcare providers for better disease management.
“Tens of millions of Americans suffer from migraine, and offering Nerivio to CMPP members supports our mission to provide safe, effective, and clinically validated relief to as many people as possible,” said Jen Stanton, Executive Director of Market Access at Theranica. “We hope this inspires other major retailers to bridge the gap between their customers and the effective migraine treatment they need.”
Theranica is a digital prescription therapy company dedicated to creating effective, safe, affordable, and low-side-effect therapies for idiopathic pain. The company’s award-winning flagship product, Nerivio®, is the first FDA-cleared, smartphone-controlled, wearable prescription device for the acute treatment of migraine, and already serves more than 30,000 migraine sufferers worldwide. UNITED STATES, including teens and veterans. Theranica is expanding its proprietary technology to develop solutions for other idiopathic pain conditions. Nerivio has received FDA clearance and CE Mark for use in the acute treatment of episodic and chronic migraine in adult and adolescent patients.
Learn more by visiting our websites, theranica.com, nerivio.com and follow us on LinkedIn, Twitter, instagram and Facebook.